Medtronic plc (NYSE: MDT) has had a busy 2020, but the global device manufacturer doesn’t seem to be slowing down. On June 15, the company announced it acquired Medicrea (OTCMKTS: MRNTF) for $158.7 million, or $8 a share. This acquisition will strengthen Medtronic’s position as a global innovator in enabling technologies and solutions for spine surgery.  

Medicrea leads the design, integrated manufacture, and distribution of more than 30 510(k) cleared implant technologies, utilized in over 175,000 spinal surgeries to date. It has 175 employees worldwide, including 35 employees in New York City. The company also has a modern manufacturing facility in Lyon, France, housing the development and production of 3D-printed titanium patient-specific implants. Medicrea generates revenue of roughly $37.07 million annually.  

Medicrea’s product portfolio includes MEDICREA UNID ASI (Adaptive Spine Intelligence), which is designed to support surgeon workflow in pre-operative planning and create personalized implant solutions for surgery. The Medicrea solution uses predictive modeling and algorithms that measure and digitally reconstruct the spine to its optimal profile.  

Medtronic has announced a few deals in 2020, particularly in the first quarter, according to DSO. In February, the company purchased Digital Surgery, a leader in surgical artificial intelligence (AI), data and analytics, and digital education and training, for an undisclosed sum. Its surgical simulation software allows healthcare providers a safe and effective way to learn surgery, instantly test their knowledge, and rehearse for surgery. The acquisition of Digital Surgery boosted Medtronic’s robotic-assisted surgery platform.  

In early January, Medtronic purchased Stimgenics, LLC, which pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM). The therapy, which is delivered via the Medtronic Intellis platform, is a new programming option to treat patients with chronic pain. Preclinical studies of DTM have shown a statistically significant reversal of pain behaviors. That deal could help Medtronic diversify its product portfolio beyond spinal surgery.